Cidara Announces Pricing of Upsized Public Offering of Common Stock
SAN DIEGO, June 24, 2025 (GLOBE NEWSWIRE) — Cidara Therapeutics, Inc. (“Cidara”) (Nasdaq: CDTX), a biotechnology company using its proprietary…
Pharmaceuticals, Biotechnology and Life Sciences
SAN DIEGO, June 24, 2025 (GLOBE NEWSWIRE) — Cidara Therapeutics, Inc. (“Cidara”) (Nasdaq: CDTX), a biotechnology company using its proprietary…
Following the reverse share split, the Company will have approximately 534,600 outstanding shares, out of which approximately 516,727 will be…
LONG BEACH, Calif. and TORONTO, June 24, 2025 (GLOBE NEWSWIRE) — Glass House Brands Inc. (“Glass House” or the “Company”)…
CUE-401, a first-in-class bispecific molecule designed to induce and expand Tregs in vivo through the co-activity of transforming TGF-β and…
GAITHERSBURG, Md., June 24, 2025 (GLOBE NEWSWIRE) — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a…
CARSON CITY, Nev., June 24, 2025 (GLOBE NEWSWIRE) — BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company…
NORWOOD, Mass., June 24, 2025 (GLOBE NEWSWIRE) — Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced…
– PDUFA action date set for October 25, 2025 – – sNDA being reviewed under FDA’s RTOR program – – Revumenib…
CHICAGO, June 24, 2025 (GLOBE NEWSWIRE) — Abvance Therapeutics, a biotechnology company developing next-generation glucagon analogs and therapies to prevent…
Aggregated presentation by day and by market Statement of transactions in own shares…